Literature DB >> 18430368

Chronic activation of neutral ceramidase protects beta-cells against cytokine-induced apoptosis.

Qun Zhu1, Jun-Fei Jin, Xiao-Hong Shan, Cui-Ping Liu, Xiao-Dong Mao, Kuan-Feng Xu, Chao Liu.   

Abstract

AIM: To investigate the activity and expression of neutral ceramidase (N-CDase) in the insulin-secreting cell line INS-1 and its role in the cellular response to cytokines.
METHODS: HPLC, Western blotting, and quantitative real-time PCR were performed to detect the activity and expression of N-CDase in INS-1 cells treated with a cytokine mixture (5 ng/mL interleukin-1beta, 10 ng/mL TNF-alpha, and 50 ng/mL interferon-gamma). The expression and activity of N-CDase in the INS-1 cells were specifically inhibited using N-CDase-siRNA transfection. Annexin V-fluorescein- isothiocyanate/propidium iodide flow cytometry was used to assess apoptosis in the INS-1 cells.
RESULTS: The INS-1 cells exhibited some basal N-CDase activity, and cytokines induced a time-dependent delay in the activation of NCDase. As a result, the activation of N-CDase was first detectable at 8 h after stimulation. It peaked at 16 h and remained elevated at 24 h. Cytokines also upregulated the mRNA and protein expression of N-CDase in the INS-1 cells. Furthermore, when N-CDase activity was inhibited by RNA interference, cytokine-induced apoptosis in the INS-1 cells was markedly increased.
CONCLUSION: The N-CDase pathway is active in INS-1 cells, and the chronic activation of N-CDase is involved in the pathological response of beta-cells to cytokines, potentially providing protection against cytokine toxicity.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18430368     DOI: 10.1111/j.1745-7254.2008.00781.x

Source DB:  PubMed          Journal:  Acta Pharmacol Sin        ISSN: 1671-4083            Impact factor:   6.150


  8 in total

1.  Essential roles of neutral ceramidase and sphingosine in mitochondrial dysfunction due to traumatic brain injury.

Authors:  Sergei A Novgorodov; Christopher L Riley; Jin Yu; Keith T Borg; Yusuf A Hannun; Richard L Proia; Mark S Kindy; Tatyana I Gudz
Journal:  J Biol Chem       Date:  2014-03-21       Impact factor: 5.157

2.  Discovery and evaluation of inhibitors of human ceramidase.

Authors:  Jeremiah M Draper; Zuping Xia; Ryan A Smith; Yan Zhuang; Wenxue Wang; Charles D Smith
Journal:  Mol Cancer Ther       Date:  2011-09-01       Impact factor: 6.261

Review 3.  Drug targeting of sphingolipid metabolism: sphingomyelinases and ceramidases.

Authors:  Daniel Canals; David M Perry; Russell W Jenkins; Yusuf A Hannun
Journal:  Br J Pharmacol       Date:  2011-06       Impact factor: 8.739

Review 4.  PAQRs: a counteracting force to ceramides?

Authors:  William L Holland; Philipp E Scherer
Journal:  Mol Pharmacol       Date:  2009-01-21       Impact factor: 4.436

5.  Loss of neutral ceramidase increases inflammation in a mouse model of inflammatory bowel disease.

Authors:  Ashley J Snider; Bill X Wu; Russell W Jenkins; Jonathan A Sticca; Toshihiko Kawamori; Yusuf A Hannun; Lina M Obeid
Journal:  Prostaglandins Other Lipid Mediat       Date:  2012-08-31       Impact factor: 3.072

6.  Neutral ceramidase-enriched exosomes prevent palmitic acid-induced insulin resistance in H4IIEC3 hepatocytes.

Authors:  Qun Zhu; Rongping Zhu; Junfei Jin
Journal:  FEBS Open Bio       Date:  2016-10-20       Impact factor: 2.693

Review 7.  Roles of ceramide and sphingolipids in pancreatic β-cell function and dysfunction.

Authors:  Ebru Boslem; Peter J Meikle; Trevor J Biden
Journal:  Islets       Date:  2012 May-Jun       Impact factor: 2.694

Review 8.  Sphingolipids in Type 1 Diabetes: Focus on Beta-Cells.

Authors:  Ewa Gurgul-Convey
Journal:  Cells       Date:  2020-08-04       Impact factor: 6.600

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.